PMID- 31517617
OWN - NLM
STAT- MEDLINE
DCOM- 20200212
LR  - 20200212
IS  - 1336-0329 (Electronic)
IS  - 1210-0668 (Linking)
VI  - 53
IP  - 1
DP  - 2019 Jan 1
TI  - The effect of peptide tyrosine tyrosine (PYY3-36), a selective Y2 receptor 
      agonist on streptozotocin-induced diabetes in albino rats.
PG  - 26-33
LID - /j/enr.2019.53.issue-1/enr-2019-0004/enr-2019-0004.xml [pii]
LID - 10.2478/enr-2019-0004 [doi]
AB  - OBJECTIVE: The aim of the present study was to assess the effect of the PYY3-36, 
      as a potential therapy for the type 2 diabetes mellitus (T2DM), induced by high 
      fat diet (HFD) and an intraperitoneal (i.p.) administration of streptozotocin 
      (STZ) in albino rats. METHODS: Forty adult male albino Wistar rats were divided 
      into: 1) control group (C, in which the rats were fed with a standard diet and 
      received vehicle; 2) diabetic group (D, in which T2DM was induced by feeding the 
      rats with HFD for four weeks followed by a single i.p. injection of 35 mg/kg STZ, 
      this group was also allowed to have HFD till the end of the study; and 3) 
      D+PYY3-36 group (in which the diabetic rats were treated with 50 microg/kg i.p. 
      PYY3-36 twice a day for one week). Food intake, water intake, body weight (b.w.), 
      visceral fat weight (VFW), liver glycogen content, serum levels of glucose, 
      insulin, and interleukin-6 (IL-6), were measured. Homeostatic-model assessment of 
      insulin resistance (HOMA-IR) was estimated. The gene expression of the 
      hypothalamic neuropeptide Y (NPY) and visceral nuclear factor kappa B (NF-kappaB) 
      were assessed by a reverse transcription polymerase chain reaction (RT-PCR). 
      RESULTS: The PYY3-36 administration to the diabetic group of rats significantly 
      increased the serum insulin levels and liver glycogen content, decreased the body 
      weight, VFW, food intake, water intake, serum levels of the glucose, IL-6, and 
      HOMA-IR. It also decreased the expression of both the hypothalamic NPY and the 
      visceral fat NF-kappaB. CONCLUSION: With respect to the fact of improved insulin 
      release and enhanced insulin sensitivity (an effect that may be mediated via 
      suppressing accumulation of visceral fat and inflammatory markers), in the rats 
      treated with PYY3-36, the PYY3-36 might be considered for the future as a 
      promising therapeutic tool in T2DM.
FAU - Abdel-Hamid, Heba A
AU  - Abdel-Hamid HA
AD  - Physiology Department, Faculty of Medicine, Minia University, Misr-Aswan 
      Road,El-Minia, Egypt.
FAU - Abdalla, Mona M I
AU  - Abdalla MMI
AD  - Physiology Department, Faculty of Medicine, Minia University, Misr-Aswan 
      Road,El-Minia, Egypt.
AD  - Physiology Department, Faculty of Medicine, MAHSA University, Malaysia.
FAU - Zenhom, Nagwa M
AU  - Zenhom NM
AD  - Biochemistry Department, Faculty of Medicine, Minia University, Misr-Aswan 
      Road,El-Minia, Egypt.
FAU - Ahmed, Rasha F
AU  - Ahmed RF
AD  - Biochemistry Department, Faculty of Medicine, Minia University, Misr-Aswan 
      Road,El-Minia, Egypt.
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Endocr Regul
JT  - Endocrine regulations
JID - 9112018
RN  - 0 (Blood Glucose)
RN  - 0 (Peptide Fragments)
RN  - 0 (Receptors, Neuropeptide Y)
RN  - 0 (neuropeptide Y2 receptor)
RN  - 106388-42-5 (Peptide YY)
RN  - 123583-37-9 (peptide YY (3-36))
RN  - 5W494URQ81 (Streptozocin)
SB  - IM
MH  - Adiposity/drug effects
MH  - Animals
MH  - Blood Glucose/drug effects/metabolism
MH  - Body Weight/drug effects
MH  - Diabetes Mellitus, Experimental/chemically induced/*metabolism/pathology
MH  - Drinking/drug effects
MH  - Eating/drug effects
MH  - *Insulin Resistance/physiology
MH  - Intra-Abdominal Fat/drug effects/metabolism/pathology
MH  - Male
MH  - Organ Size/drug effects
MH  - Peptide Fragments/*pharmacology
MH  - Peptide YY/*pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Receptors, Neuropeptide Y/agonists
MH  - Streptozocin
OTO - NOTNLM
OT  - NF-kappaB and NPY
OT  - PYY
OT  - high fat diet
OT  - insulin resistance
EDAT- 2019/09/14 06:00
MHDA- 2020/02/13 06:00
CRDT- 2019/09/14 06:00
PHST- 2019/09/14 06:00 [entrez]
PHST- 2019/09/14 06:00 [pubmed]
PHST- 2020/02/13 06:00 [medline]
AID - /j/enr.2019.53.issue-1/enr-2019-0004/enr-2019-0004.xml [pii]
AID - 10.2478/enr-2019-0004 [doi]
PST - ppublish
SO  - Endocr Regul. 2019 Jan 1;53(1):26-33. doi: 10.2478/enr-2019-0004.